|Year : 2021 | Volume
| Issue : 2 | Page : 78-88
Headache in daily practice: What a physician needs to know
Pooja Mailankody, Ashok Vardhan Reddy Taallapalli, Girish Baburao Kulkarni
Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
|Date of Submission||14-Oct-2020|
|Date of Decision||13-Nov-2020|
|Date of Acceptance||14-Nov-2020|
|Date of Web Publication||21-Apr-2021|
Prof. Girish Baburao Kulkarni
Department of Neurology, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka
Source of Support: None, Conflict of Interest: None
Headache is a common presenting complaint encountered in the outpatient as well as inpatient settings. Appropriate diagnosis and treatment of the commonly encountered primary headaches, timely evaluation for secondary causes, and patient education are the management's cornerstones. Our review aims to summarize the key diagnostic features and treatment of primary headaches and discuss the red flags that aid in the diagnosis of secondary headaches. For this, we searched the PubMed database using the keywords “Primary headache,” “Primary headache AND Diagnosis,” “Primary headache AND Treatment,” “Red flags AND Headache,” “Secondary Headaches.” Those articles written in English and were available in full text were reviewed. In this review, in addition to the clinical and management aspects, we have also elucidated the diagnosis and management of headache in special situations such as pregnancy and menstruation, headache in the emergency room, status migrainosus, and newer developments in the therapeutic armamentarium of headache. We have also tried to simplify the approach to headaches seen in routine outpatient clinics and emergency settings and develop a structured approach for diagnosis and management.
Keywords: Analgesics, headache, migraine, tension-type headache, triptans
|How to cite this article:|
Mailankody P, Reddy Taallapalli AV, Kulkarni GB. Headache in daily practice: What a physician needs to know. APIK J Int Med 2021;9:78-88
|How to cite this URL:|
Mailankody P, Reddy Taallapalli AV, Kulkarni GB. Headache in daily practice: What a physician needs to know. APIK J Int Med [serial online] 2021 [cited 2021 May 14];9:78-88. Available from: https://www.ajim.in/text.asp?2021/9/2/78/314201
| Introduction|| |
Headache is a common complaint encountered by the physicians in both outpatient and emergency settings. Accurate diagnosis is key to the management. Among the patients, who seek health-care services for headache, more than 80% go to the primary healthcare providers. Due to various barriers related to the care of headache disorders, the diagnosis and treatment are suboptimal. Even in a developed country like the United States, more than half of the patients never received a formal diagnosis. Headache may commonly be a disease itself and may recur (primary) or may be a symptom of an underlying disorder that may occasionally be life-threatening (secondary). Identifying the red flags and appropriate management of the secondary cause is important. Empowering the physicians in proper management will help the patients and the health care system immensely in tackling this burden.
| Definition and Classification|| |
The term headache is used to describe pain or discomfort in the head or neck above the orbitomeatal line. The crude 1-year prevalence of headache is 63.9% in Karnataka. Headache is considered primary when there is no other causative disorder. When another disease causes a headache, it is considered secondary. Migraine, tension-type headache (TTH), and trigeminal autonomic cephalalgia (TAC) are the major primary headache disorders. Over 15% of the population is affected by migraine attacks, and 10% of them suffer from weekly attacks. According to the Global burden of Disease Study 2010, the global prevalence of migraine is 14.7%. TTH and migraine were the second and third most prevalent disorders worldwide. Secondary headache occurs in close temporal relation to another disorder that is known to cause a headache. It usually resolves within 3 months after successful treatment or spontaneous remission of the causative disorder.
| Why Do We Need A “Classification”?|| |
Headache is a common presenting complaint encountered in various clinical settings. Uniformity of diagnosis across the globe helps better understanding of the burden and development of better ways of addressing the burden. A uniform classification is required for the proper diagnosis, correct treatment, and research.
The most recent classification, the ICHD3 is available in a user-friendly online version (www.ichd-3.org) [Table 1]. This resource enables easy and quick diagnosis of headaches in the outpatient setting, facilitating the patient's appropriate and tailored treatment. Primary headache needs to be distinguished from secondary headache. Even among primary headaches, the treatment depends on the type of headache.
|Table 1: The international classification of headache disorders 3 classification of headache disorders|
Click here to view
| Pathophysiology of Headache|| |
Cranial nerves carry the pain fibers. Part of the dura at the brain's base, proximal segment cerebral arteries and venous sinuses, middle meningeal arteries and superficial temporal arteries, external periosteum of the skull, skin, subcutaneous tissues, and extracranial arteries are the pain-sensitive structures around the brain. Traction on major intracranial vessels, dilation or distension of the intracranial or extracranial arteries, inflammation adjacent to the pain-sensitive structures, and structural involvement of the cranial or cervical nerves are some of the mechanisms of headache.
Migraine has a neurovascular basis. It is an abnormal state of the brain with secondary vascular effects. Aura corresponds to the cortical spreading depression (CSD). The CSD is a slowly propagating wave (2–6 mm/min) of depolarization of neurons and glia, and this wave is followed by a prolonged cessation (15–30 min) of cortical activity. It is believed to originate from the cerebral cortex, hippocampus, and cerebellum.
Neuropeptides such as calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide, and substance P are discharged from the trigeminal afferents, possibly in response to CSD, and this leads to the dilation of blood vessels and extravasation of plasma proteins leading to “sterile” neurogenic inflammation. The activation of the trigeminal nucleus in the brainstem leads to migraine features as the nucleus has connections with other parts of the brain like the thalamus, which has projections to the somatosensory cortex and limbic system. The trigeminal nucleus also has connections with the hypothalamus and superior salivatory nucleus, which probably explains the autonomic features in migraine.
A strong family history suggests a genetic component to migraine risk. To summarize, both genetic and environmental factors contribute to the pathogenesis of migraine.
| Common Primary Headache Disorders|| |
In a door-to-door survey, Kulkarni et al. found that the crude 1-year prevalence of definite migraine was 25.6% in Karnataka's urban and rural populations. The prevalence of migraine was more among females (32.4%) compared to males (18.6%) and more among those from rural areas (29.7%) compared to those from urban areas (21.9%).
Migraine is a recurrent disabling neurovascular disorder characterized by a unilateral, pulsating headache of moderate to severe intensity, which worsens on exertion and is accompanied by nausea and/or vomiting, photophobia, and phonophobia [Table 2]. Each attack's duration may range from 4 to 72 h, and five such attacks are required to diagnose episodic migraine. The most common type of migraine is common migraine or migraine without aura. Migraine with aura or classic migraine is characterized by headache preceded by a disruption of nervous function (mostly visual). The ratio of classic to common migraine is 1:5. Nevertheless, it is less prevalent in the Indian context. Aura is seen in <5% of migraine patients in India (unpublished observation).
The most common aura of migraine is visual and is characterized by positive moving visual symptoms with scintillating, shimmering, jagged edges, and lasts for typically 20–30 min. Characteristically, the aura symptoms gradually build up over 5–10 min and usually last up to 1 h and followed or preceded by the characteristic migraine headaches, and aura symptoms are recurrent. When a patient has the first episode of aura, it must be distinguished from a seizure and a stroke. Positive visual symptoms also characterize occipital seizures. Nevertheless, they last only for a few seconds. In an occipital transient ischemic attack (TIA), hemianopia or blindness are the visual symptoms. They appear and disappear suddenly and last for a few minutes. Other seizure phenomena may accompany the visual symptoms in case of an occipital seizure and other vertebrobasilar symptoms in an occipital TIA case.,
Prodromal symptoms like yawning, blurred vision, sensitivity to light, and or sound, nausea may occur a few hours before the onset of headache in a patient with migraine. Mood changes and fatigue may occur after the headache improves, and may last for up to 48 h. Emotional stress, changes in sleep pattern, travel, skipping a meal, odors, menstrual cycle, bright light, weather, exercise, or overactivity, some food items were the triggers identified by Kulkarni et al. during their study (unpublished observation). Certain features of migraine are peculiar to the Indian population, such as migraine triggered by a head bath. Migraine is called chronic when it occurs on more than 15 days per month for at least 3 months. The diagnosis of migraine remains clinical; based on the criteria. No investigation can confirm the diagnosis.
Treatment of migraine
Migraine can be managed with pharmacological as well as nonpharmacological methods. Acute management is for immediate pain relief, and prophylaxis decreases the frequency, duration, and severity of episodes.
Avoidance of triggers, 150 min of exercise per week, and sleep hygiene are essential in managing migraine episodes., Relaxation techniques and yoga are also important nonpharmacological tools in treating migraine., Maintaining a headache diary helps detect a pattern and assess response to treatment.
| Pharmacological Measures|| |
The objective of acute treatment is to restore full function within 2 h of onset and ensuring no recurrence for the next 24 h. Optimum acute treatment is also important to prevent the conversion of episodic to chronic migraine. Specific agents used for migraine treatment are triptans. They act on 5-hydroxytryptamine receptor 1D and prevent the release of CGRP. Nonsteroidal anti-inflammatory drugs (NSAIDs) and antiemetics are the nonspecific drugs used for acute control. Drugs can be administered through oral, subcutaneous, intravenous, and intramuscular routes. Intranasal, sublingual routes and skin patches are some of the newer delivery routes for certain drugs [Table 3]. If the time to peak is <30 min or the headache is accompanied by severe nausea and vomiting, nonoral routes are preferred.
The goal is to reduce headache frequency, severity, and duration. Institution of timely and appropriate acute and prophylactic medication is important to prevent the development of chronic migraine and medication overuse headache (MOH) [Table 3] and [Table 4]., In the case of a middle-aged woman with migraine and depression, amitriptyline may the drug of choice and not propranolol or flunarizine. On the contrary, for a young migraineur who is a driver by occupation, propranolol is the drug of choice.
Understanding the role of CGRP in migraine has led to the development of molecules targeting both CGRP and its receptor. Some of these drugs which are being currently used on a trial basis will soon become available for the management of both acute and preventive treatment of migraine [Table 5] and [Table 6].,,,,,,,,,,,,
Migraine and menstruation
Menstrual migraine could be pure menstrual migraine wherein headache occurs only during the menstruation (−2 to +3 days) and at no other time during the cycle. More common is the menstrually related migraine in which the attacks occur throughout the cycle but increase in the frequency or intensity during the menstruation. NSAIDs are used for acute and prophylactic treatment for both types of menstrual migraines. For pure menstrual migraine, hormonal treatment may help in prophylaxis.
Migraine in pregnancy
More than 80% of the patients with migraine have an improvement in their headache during pregnancy. The use of medications must be minimized as much as possible. Rest, relaxation therapy, and biofeedback may be tried for mild attacks. Paracetamol can be used for abortive treatment. In general, prophylaxis is discontinued before pregnancy or after diagnosis of pregnancy as most of them improve during pregnancy. However, if the attacks are frequent, severe, or prolonged and do not respond to abortive therapy, beta-blockers like propranolol and tricyclic antidepressant, like amitriptyline are considered first, and second-line agents, respectively. An attempt should be made to avoid them during the first trimester and explain the possibility of an effect on developing fetus before starting them. Greater occipital nerve block has been successfully tried for the management of migraine during pregnancy. There is scarce data regarding the use of non-invasive stimulation devices in pregnancy. Nevertheless, anecdotal reports suggest that single-pulse transcranial magnetic stimulation is safe for acute migraine in pregnancy.
Headache occurring during the puerperal stage could be due to other causes such as cerebral venous thrombosis, preeclampsia/eclampsia, posterior reversible encephalopathy syndrome, postdural puncture headache, pituitary apoplexy, subarachnoid hemorrhage, and other stroke syndromes. Hence, imaging must be done to rule out secondary causes of headache. If imaging is normal, migraine has to be considered when the attacks are recurrent and satisfy the diagnosis criteria. The safety of abortive and prophylactic drugs during breastfeeding should be ascertained before prescribing.
| Status Migrainosus|| |
Status migrainosus is defined as a debilitating migraine that lasts for more than 72 h in a known patient of migraine. The differential diagnosis for status migrainosus are idiopathic intracranial hypertension, subdural hematoma, brain tumor, brain abscess, cervical artery dissection, meningitis, sphenoid sinusitis, and acute glaucoma. History and a normal neurological examination help in the diagnosis. Subcutaneous sumatriptan is the treatment of choice. Intravenous fluids, NSAIDs, antiemetics, corticosteroids, nerve blocks especially greater occipital nerve block, are other treatment options for status migrainosus in emergency settings. If the patient has severe dehydration, intractable headache or vomiting, poor response to emergency treatment, very high headache-related disability, inpatient care may be considered.
| Tension-type Headache|| |
TTH, the most common type of headache, is characterized by a nonpulsating headache, bilateral and mild to moderate in intensity [Table 2]. At least ten episodes are required to make a diagnosis. The duration can range from 30 min to 7 days. There will be no nausea or vomiting, as seen in migraine. The lifetime prevalence of TTH can be as high as 78%. A door to door survey by Kulkarni et al. found that the 1-year crude prevalence of TTH was 34.8%. Based on the frequency of occurrence, TTH can be classified as infrequent episodic, frequent episodic, and chronic TTH.
The TTH can begin at any age, and the peak prevalence is between the age of 40 and 49 years. Pathophysiology of TTH remains unclear, though it is generally agreed that pericranial muscles and fascia contribute to the genesis of the headache. The pain threshold is lower in patients with chronic TTH. A large number of patients with chronic TTH have tenderness of the cervical and the pericranial muscles. Migraine may also be holocranial and hence may be misdiagnosed as TTH. Hence, the differentiation should be made between the two by carefully enquiring about the migrainous features.
The management includes nonpharmacological as well as pharmacological measures. Avoidance of triggers, if any, stress management, including relaxation techniques and biofeedback, are helpful. Analgesics especially NSAIDs, are used in the treatment of acute attacks. If the patient has a headache on at least 2–3 days per month, a preventive treatment can be given, and amitriptyline is the drug of choice.
| Other Types of Primary Headaches|| |
Sharp pain occurring on one side and accompanied by autonomic symptoms on the same side constitute TAC. The TACs differ from each other in terms of duration of the attack, frequency of occurrence, and treatment [Table 2].
Headache occurring on 15 or more days per month for at least 3 months is a chronic headache. Chronic headaches are a severely disabling long-term condition with higher symptom frequency and severity than episodic headaches. Chronic headache includes both primary and secondary headache disorder. The primary headache could be chronic migraine, chronic TTH, hemicrania continua, or new daily persistent headache (NDPH). NDPH is characterized by distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 h. The pain is usually bilateral and characterized by a tight or squeezing quality of mild-to-moderate intensity. Secondary causes should be ruled out by identifying the red flags and appropriate investigations. Identification and treatment of medical and psychiatric comorbidities are important in the management of chronic headaches. Treatment details of primary headaches are given in [Table 2] and [Table 3].
| Secondary Headaches and Red Flags|| |
Secondary headache reduces or resolves within 3 months of successful treatment or spontaneous remission of the underlying cause. A timely diagnosis of secondary headache is often rewarding as many secondary causes are treatable and can prevent life-threatening complications when managed early [Table 7]. “Red flags” help in the identification of secondary causes of headache. The presence of papilledema is a “red flag” that tells us that it is not a migraine. If not diagnosed on time, the patient can develop visual loss. When the headache occurs abruptly, or there is a recent change in the pattern, a secondary cause should be considered. Furthermore, positional headache (worsens when upright) and headache precipitated by coughing or sneezing should alert the physician that it is not a primary headache. Systemic symptoms like fever, weight loss, an immunocompromised state like human immunodeficiency virus, present or past history of malignancy, co-existent neurological deficits, age of onset of headache more than 50 years, and occurrence during pregnancy and puerperium are some of the red flags for diagnosis of secondary headache [Figure 1], [Figure 2], [Figure 3], [Figure 4] and [Table 8].
|Table 7: Clinical features, investigations, and treatment of common secondary headaches|
Click here to view
|Figure 1: Cerebral venous thrombosis. (a) Axial contrast enhanced computed tomography of the brain shows empty delta sign (arrow) due to the enhancement of the dura and nonenhancement of the thrombus. (b) Mixed density lesion in the left frontoparietal region suggestive of hemorrhagic infarct|
Click here to view
|Figure 2: Idiopathic intracranial hypertension. (a) T2 axial sections-kinking of the bilateral optic nerves (arrow). (b) Magnetic resonance venogram reveals bilateral sigmoid sinus stenosis in idiopathic intracranial hypertension (arrow). (c) T1 sagittal image shows empty sella (arrow)|
Click here to view
|Figure 3: Intracranial hemorrhage. (a) Axial plain computed tomography brain shows hyperdensity in the left cerebellar hemisphere and brainstem obliterating the 4th ventricle suggestive of acute hemorrhage. (b) Axial computed tomography brain plain shows right parietal lobar hemorrhage. (c) Plain computed tomography reveals hyperdensity across bilateral sylvian fissures (arrows) and inter-hemispheric fissure (arrow head) suggestive of disuse subarachnoid hemorrhage|
Click here to view
|Figure 4: Headache-an approach. TTH: Tension type headache, TAC: Trigeminal autonomic cephalalgia|
Click here to view
Thunderclap headache (TCH) is a severe headache that reaches maximum intensity in <1 min. Subarachnoid hemorrhage, cerebral venous thrombosis, intracranial hypotension, cervical artery dissection, pituitary apoplexy, brain infections, intake of vasoactive substances like cannabis, cocaine, amphetamines, nasal decongestants reversible cerebral vasoconstriction syndrome are the various causes of TCH.
Medication overuse headache
MOH is a headache that occurs as a result of regular overuse of medications for acute control. Once the overuse is stopped, the headache mostly resolves. The MOH is a secondary headache and develops in patients with preexisting primary headache disorder that occurs on ≥15 days per month for >3 months. The most common primary headache disorder associated with MOH is migraine. The prevalence of MOH in the general population is 1%–2%. MOH can be simple or complex. Short-term overuse with small amounts, minimal psychiatric comorbidity, and no history of relapse after withdrawal suggest simple MOH, whereas significant psychiatric comorbidity history of relapse suggests complex MOH., Combination analgesics, opioids, and triptans are associated with increased risk of developing MOH. More than ten headache days monthly, female gender, comorbid psychiatric disorders or chronic pain conditions, lower socioeconomic status, and dependency behavior are the risk factors for MOH development. Patient education regarding the “too frequent” use of acute medications, risk factors, and consequences of medication overuse is the first step in the management of MOH. Further, detoxification with abrupt cessation of the overused drugs followed by the initiation of prophylaxis with topiramate or botulinum toxin will be required for the treatment of MOH.
Headache in the emergency room
Headache is a common complaint in the emergency room. Primary headache disorders such as migraine, TTH, TACs, and secondary headaches caused by sinusitis, hypertension, subarachnoid hemorrhage, neuro infection, or malignancy can present to the emergency department. Among the primary headaches presenting to the emergency, migraine is the most common cause.,, Patients with migraine may also present to the emergency when the abortive or the rescue medications fail. A detailed history and examination can help in the diagnosis of secondary headaches, which can be confirmed by appropriate investigations [Table 7] and [Table 8]. The treatment depends on the underlying etiology of the headache [Table 3] and [Table 7].,,
Approach to headache
History is the cornerstone of the diagnosis. Detailed interview regarding the onset, progression, nature, duration, frequency, and severity of headache can give a clue to the diagnosis. General physical examination, including the vitals and neurological examination, are mandatory for every patient with headache. For example, elevated BP and bradycardia may be due to Cushing's reflex in raised intracranial tension. Horner's syndrome may suggest a diagnosis of cervical artery dissection. Work up for secondary causes will be guided by the key features in history and examination. For primary headaches, both diagnosis and management rely entirely on history [Figure 4] and [Table 8].
Maintaining a diary by the patient helps in objective documentation of the details, which might be forgotten otherwise. The diary will help in determining the pattern and frequency, thereby guiding the physician to choose the most appropriate therapy [Figure 5]. The duration and frequency may help in the diagnosis of certain types of headaches like a menstrual migraine.
Use of complementary and alternative medicine in headache
The National Institutes of Health defines complementary and alternative medicine (CAM) as a group of diverse medical and health care systems, practices, and products that are not generally considered conventional medicine. A large number of patients (30%–80%) use CAM in addition to the conventional treatment for the management of headaches., Patients who use CAM often report that the CAM is more “useful” than conventional care. Mind-body therapies such as deep breathing exercises, meditation, yoga, relaxation exercise, guided imagery, herbal supplements, chiropractic, massage, homeopathy, Ayurveda, and acupuncture are some of the CAM used by patients. More studies are required to evaluate the benefits of CAM use in migraine.
Barriers to headache care in the country
Various patient-related and physician-related barriers are responsible for the suboptimal headache care in our country in addition to the problems such as poverty, overcrowding, and poor education. Myths and misconceptions like headaches are due to eye or sinus problems, financial constraints, fear of side effects, self-medication, frequent change of doctors lead to poor control of headaches. Physician-related issues like the wrong drug, underdosing, and lack of patient education are also barriers to headache care in our country.
| Conclusion|| |
Headache can be the presenting symptom in outpatient as well as emergency settings. Physicians need to be well-versed in diagnosing and treating common primary headache disorders, identifying the red flags, and timely management of secondary headaches. We summarized the characteristics of primary headaches, current and future therapeutic options for managing headaches, secondary causes, and approach to headaches. We also reviewed the common drugs used for acute control and prophylaxis, their dosage side effects, and contraindications, which will help day-to-day practice. Being cautious in special situations like a migraine in pregnancy and puerperium, considering the comorbidities while prescribing medications, and timely referral to the specialist when treatment response is poor will help in the appropriate management of headaches.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kulkarni GB, Rao GN, Gururaj G, Stovner LJ, Steiner TJ. Headache disorders and public ill-health in India: Prevalence estimates in Karnataka State. J Headache Pain 2015;16:67.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al
. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9.
Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd
edition. Cephalalgia 2018;38:1-211.
Rao GN, Kulkarni GB, Gururaj G, Stovner LJ, Steiner TJ. The burden attributable to headache disorders in India: Estimates from a community-based study in Karnataka State. J Headache Pain 2015;16:94.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002;346:257-70.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al
. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
Ropper AH, Samuel MA, Klein JP. Headache and other craniofacial pains. In: Sydor AM, Davis KJ, editors. Adams and Victor's Principles of Neurology. 10th
ed. United States: McGraw-Hill Education; 2014. p. 169-72.
Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol 2013;75:365-91.
Ward TN. Migraine diagnosis and pathophysiology. Continuum (Minneap Minn) 2012;18:753-63.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017;97:553-622.
Gardner KL. Genetics of migraine: An update. Headache 2006;46 Suppl 1:S19-24.
Panayiotopoulos CP. “Migralepsy” and the significance of differentiating occipital seizures from migraine. Epilepsia 2006;47:806-8.
Ravishankar K. 'Hair wash' or 'head bath' triggering migraine Observations in 94 Indian patients. Cephalalgia 2006;26:1330-4.
Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn) 2018;24:1052-65.
Kisan R, Sujan M, Adoor M, Rao R, Nalini A, Kutty BM, et al
. Effect of Yoga on migraine: A comprehensive study using clinical profile and cardiac autonomic functions. Int J Yoga 2014;7:126-32.
] [Full text]
Tepper SJ. Acute treatment of migraine. Neurol Clin 2019;37:727-42.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache 2015;55:3-20.
Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn) 2012;18:764-82.
de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 2020;211:107528.
Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, et al
. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018;38:215-24.
Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM. DFN-02, Sumatriptan 10 mg nasal spray with permeation enhancer, for the acute treatment of migraine: A randomized, double-blind, placebo-controlled study assessing functional disability and subject satisfaction with treatment. CNS Drugs 2019;33:375-82.
Bhagawati ST, Chonkar AD, Dengale SJ, Reddy SM, Bhat K. Bioavailability enhancement of rizatriptan benzoate by oral disintegrating strip: In vitro
and In vivo
evaluation. Curr Drug Deliv 2016;13:462-70.
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al
. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 2018;91:e2222-32.
Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019;39:3-14. doi: 10.1177/0333102418811573. Epub 2018 Nov 17. PMID: 30449151; PMCID: PMC6348457.
Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al
. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010;9:373-80.
Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, Dorlas S, et al.
PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. 2018;91:e364-e373. doi: 10.1212/WNL.0000000000005857. Epub 2018 Jun 15. PMID: 29907608; PMCID: PMC6070381.
Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al
. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology 2017;88:1250-5.
Friedman BW, Mohamed S, Robbins MS, Irizarry E, Tarsia V, Pearlman S, et al
. A randomized, sham-controlled trial of bilateral greater occipital nerve blocks with bupivacaine for acute migraine patients refractory to standard emergency department treatment with metoclopramide. Headache 2018;58:1427-34.
Inan LE, Inan N, Unal-Artık HA, Atac C, Babaoglu G. Greater occipital nerve block in migraine prophylaxis: Narrative review. Cephalalgia 2019;39:908-20.
Garza I, Schwedt TJ, Robertson CE, Smith JH. Headache and other craniofacial pain. In: Daroff RB, Jankovic J, Mazziotta JC and Pomeroy SL, editors. Bradley's Neurology in Clinical Practice. 7th
ed. United States of America: Elsevier. 2016. p. 1686.
MacGregor EA. Migraine in pregnancy and lactation: A clinical review. J Fam Plann Reprod Health Care 2007;33:83-93.
Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 2015;11:209-19.
Govindappagari S, Grossman TB, Dayal AK, Grosberg BM, Vollbracht S, Robbins MS. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstet Gynecol 2014;124:1169-74.
Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: A safety review. Headache 2010;50:1153-63.
Gladstone JP, Dodick DW, Evans R. The young woman with postpartum “thunderclap” headache. Headache 2005;45:70-4.
Chua AL, Grosberg BM, Evans RW. Status migrainosus in children and adults. Headache 2019;59:1611-23.
Marcus DA. Treatment of status migrainosus. Expert Opin Pharm 2001;2:549-55.
Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol 2005;20:243-9.
Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998;279:381-3.
Bendtsen L, Jensen R. Treating tension-type headache-an expert opinion. Expert Opin Pharmacother 2011;12:1099-109.
Rossi P, Vollono C, Valeriani M, Sandrini G. The contribution of clinical neurophysiology to the comprehension of the tension-type headache mechanisms. Clin Neurophysiol 2011;122:1075-85.
Chakravarty A, Mukherjee A, Roy D. Migraine pain location in adult patients from eastern India. Ann Indian Acad Neurol 2008;11:98-102.
] [Full text]
Loder E, Rizzoli P. Tension-type headache. BMJ 2008;336:88-92.
Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J, et al
. EFNS guideline on the treatment of tension-type headache-report of an EFNS task force. Eur J Neurol 2010;17:1318-25.
Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies. Headache 2013;53:427-36.
Silberstein SD, Lipton RB. Chronic daily headache including transformed migraine, chronic tension-type headache, and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff's Headache and Other Head Pain. 7th
ed. New York: Oxford University Press; 2001. p. 247-82.
Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: Challenges in clinical practice. Headache 2005;45 Suppl 1:S74-85.
Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M, et al
. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology 2019;92:134-44.
Ducros A. Thunderclap headache. BMJ 2013;346:e8557.
Shand B, Goicochea MT, Valenzuela R, Fadic R, Jensen R, Tassorelli C, et al
. Clinical and demographical characteristics of patients with medication overuse headache in argentina and chile: Analysis of the latin american section of COMOESTAS project. J Headache Pain 2015;16:83.
Kristoffersen ES, Lundqvist C. Medication-overuse headache: Epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87-99.
Saper JR, Hamel RL, Lake AE 3rd
. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005;25:545-6.
Lake AE 3rd
. Medication overuse headache: Biobehavioral issues and solutions. Headache 2006;46 Suppl 3:S88-97.
Sarchielli P, Corbelli I, Messina P, Cupini LM, Bernardi G, Bono G, et al
. Psychopathological comorbidities in medication-overuse headache: A multicentre clinical study. Eur J Neurol 2016;23:85-91.
Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: Risk factors, pathophysiology and management. Nat Rev Neurol 2016;12:575-83.
Doretti A, Shestaritc I, Ungaro D, Lee JI, Lymperopoulos L, Kokoti L, et al
. Headaches in the emergency department -a survey of patients' characteristics, facts and needs. J Headache Pain 2019;20:100.
Chu KH, Howell TE, Keijzers G, Furyk JS, Eley RM, Kinnear FB, et al
. Acute headache presentations to the emergency department: A state wide cross-sectional study. Acad Emerg Med 2017;24:53-62.
Tabatabai RR, Swadron SP. Headache in the emergency department: avoiding misdiagnosis of dangerous secondary causes. Emerg Med Clin North Am 2016;34:695.
Friedman BW, West J, Vinson DR, Minen MT, Restivo A, Gallagher EJ. Current management of migraine in US emergency departments: An analysis of the National Hospital Ambulatory Medical Care Survey. Cephalalgia 2015;35:301-9.
Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al
. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache 2016;56:911-40.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: Opioids, NSAIDs, steroids, and post-discharge medications. Headache 2012;52:467-82.
De Corso E, Kar M, Cantone E, Lucidi D, Settimi S, Mele D, et al
. Facial pain: sinus or not? Acta Otorhinolaryngol Ital. 2018;38:485-96. doi: 10.14639/0392-100X-1721. PMID: 30623894; PMCID: PMC6325651.
Patricia M. Barnes, Eve Powell-Griner, Kim McFann, Richard L. Nahin, Complementary and alternative medicine use among adults: United States, 2002, Seminars in Integrative Medicine, 2004;2:54-71.
Rossi P, Di Lorenzo G, Malpezzi MG, Faroni J, Cesarino F, Di Lorenzo C, et al
. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia 2005;25:493-506.
Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache 2011;51:1087-97.
Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, et al
. Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey. Ann Intern Med 2001;135:344-51.
Ravishankar K. Barriers to headache care in India and efforts to improve the situation. Lancet Neurol 2004;3:564-7.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]